Ketamine as an Adjunct Therapy for Refractory Cancer Pain: A Case Report

Area of Science:

• Pharmacology
• Oncology
• Pain Management

Background:

• Advanced cancer pain is a significant clinical challenge, often refractory to conventional opioid therapies.
• Refractory cancer pain leads to inadequate relief or intolerable side effects, necessitating alternative treatments.
• Opioid tolerance and hyperalgesia can complicate pain management in advanced cancer patients.

Purpose of the Study:

• To review the pharmacologic properties of ketamine as an adjunctive therapy for refractory cancer pain.
• To present a case report on the use of ketamine in a patient with advanced, opioid-refractory cancer pain.
• To highlight the therapeutic potential and clinical implications of ketamine in palliative care.

Main Methods:

• Review of ketamine's pharmacology, focusing on its role as an N-methyl-D-aspartate (NMDA) receptor antagonist.
• Presentation of a clinical case detailing ketamine administration in a patient with refractory cancer pain.
• Discussion of ketamine's efficacy, safety, and implications in the palliative care setting.

Main Results:

• Ketamine, an NMDA receptor antagonist, demonstrates unique analgesic properties.
• Low-dose, subanesthetic ketamine can be effective in managing severe, intractable pain.
• The case report illustrates the potential of ketamine to address opioid tolerance and hyperalgesia.

Conclusions:

• Ketamine shows therapeutic potential as an adjunctive treatment for refractory cancer pain.
• Subanesthetic ketamine may improve quality of life for patients with advanced cancer.
• Further investigation into ketamine's role in palliative pain management is warranted.